Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Basel Medical GroupBMGL -4.32%17 Return-on-Tangible-Asset is 2.76% as of Dec. 2025, which is 76% below its 10-year median of 11.48. GuruFocus rates BMGL with a GF Score™ of 17/100. The stock has 3 warning signs investors should review. Among 683 Healthcare Providers & Services companies, Basel Medical Group ranks worse than 86.82% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Basel Medical Group's annualizedNet Income for the quarter that ended in Dec. 2025 was $0.42 Mil. Basel Medical Group's average total tangible assets for the quarter that ended in Dec. 2025 was $15.08 Mil. Therefore, Basel Medical Group's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 2.76%.
The historical rank and industry rank for Basel Medical Group's Return-on-Tangible-Asset or its related term are showing as below:
BMGL'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -62.28 Med: 11.48 Max: 13.06
Current: -57.05
During the past 4 years, Basel Medical Group's highest Return-on-Tangible-Asset was 13.06%. The lowest was -62.28%. And the median was 11.48%.
BMGL's Return-on-Tangible-Asset is ranked worse than 86.82% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 2.43
vs BMGL: -57.05
Basel Medical Group (NAS:BMGL) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Basel Medical Group Return-on-Tangible-Asset Related Terms
Basel Medical Group Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Basel Medical Group's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basel Medical Group Return-on-Tangible-Asset Chart
BMGL vs AMS, HLYK, BICX: Return-on-Tangible-Asset Comparison
For the Medical Care Facilities subindustry, Basel Medical Group's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basel Medical Group Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Basel Medical Group's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Basel Medical Group's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 2.76% mean?
Basel Medical Group (BMGL) has a Return-on-Tangible-Asset of 2.76% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Basel Medical Group and its competitors. This is 76% below median its historical median of 11.48. According to the industry distribution chart, Basel Medical Group ranks #593 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 86.8%.
Is Basel Medical Group's Return-on-Tangible-Asset too high?
Basel Medical Group's current Return-on-Tangible-Asset of 2.76% is 76% below median its 10-year median of 11.48. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.43. Basel Medical Group's value of 2.76% is 13.6% above this industry median. Based on the distribution chart, Basel Medical Group ranks #593 out of 683 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Basel Medical Group has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Basel Medical Group's Return-on-Tangible-Asset compare to AMS and HLYK?
According to the Healthcare Providers & Services industry distribution chart, Basel Medical Group ranks #593 out of 683 companies for Return-on-Tangible-Asset. This places Basel Medical Group in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.43. Basel Medical Group's value of 2.76% is 13.6% above this benchmark. While the company's 10-year median is 11.48 vs. the industry median of 2.43, Basel Medical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.43, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Basel Medical Group's current Return-on-Tangible-Asset of 2.76% is 13.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Basel Medical Group and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basel Medical Group's current Return-on-Tangible-Asset is 2.76%, which is 76% below median its own 10-year median of 11.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basel Medical Group stock overvalued right now?
Basel Medical Group (BMGL) has a current Return-on-Tangible-Asset of 2.76%. The current Return-on-Tangible-Asset is 2.76%, which is 76% below median its 10-year median of 11.48 and 13.6% above the Healthcare Providers & Services industry median of 2.43. Basel Medical Group's overall GF Score™ is 17/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Basel Medical Group (BMGL), the current Return-on-Tangible-Asset is 2.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. The services provided by clinics include, but are not limited to, consultation, medical diagnosis and medical or surgical treatments for orthopedic, trauma, sports medicine, general practice, health screening, mental health, women's health and neurosurgical conditions and clinics are equipped with the facilities needed to perform a variety of procedures on site and minor surgical services. Key revenue is generated from Singapore.
17GF Score
Get the complete analysis for BMGL
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMGL has been successfully added to your 
